miR-149 suppresses human non-small cell lung cancer growth and metastasis by inhibiting the FOXM1/cyclinï¿½D1/MMP2 axis | Zendy

Lijiang Zhao | Zendy; Lijuan Liu | Zendy; Zheng Dong | Zendy; Jie Xiong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

miR-149 suppresses human non-small cell lung cancer growth and metastasis by inhibiting the FOXM1/cyclinï¿½D1/MMP2 axis

Author(s) -

Lijiang Zhao,

Lijuan Liu,

Zheng Dong,

Jie Xiong

Publication year - 2017

Publication title -

oncology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.094

H-Index - 96

eISSN - 1791-2431

pISSN - 1021-335X

DOI - 10.3892/or.2017.6047

Subject(s) - foxm1 , oncogene , cancer research , cyclin d1 , metastasis , mmp2 , cell cycle , biology , lung cancer , microrna , molecular medicine , cell growth , cancer , cyclin b1 , cyclin b , downregulation and upregulation , oncology , medicine , cyclin dependent kinase 1 , gene , genetics

Valid evidence has demonstrated that microRNAs have critical functions in cancer genesis and tumor progression. In the present study, aberrant expression of microRNA-149 (miR-149) was confirmed in non-small cell lung cancer (NSCLC) tissues. Low expression of miR-149 was associated with malignant clinical features and poor survival. Gain- and loss-of-function experiments demonstrated that miR-149 inhibited NSCLC tumor growth and metastasis in vitro and in vivo. Furthermore, oncogenic transcription factor FOXM1 was confirmed as a direct target of miR-149 in NSCLC. Cyclin D1 and MMP2 served as downstream targets of FOXM1 and were also inhibited by miR-149. In summary, the present study indicated that downregulation of miR-149 in NSCLC predicted poor clinical outcomes. miR-149 suppresses tumor growth and metastasis in NSCLC by inhibiting the FOXM1/cyclin D1/MMP2 signaling pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research